TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10910488

Group type: EXPERIMENTAL
Intervention: Epidural infusion of ropivacaine 2 mg/ml (group 1)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Epidural infusion of ropivacaine 3 mg/ml (group 2)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Epidural infusion of ropivacaine (both groups)
Number of subjects: 28
Study: 8757206

Group type: EXPERIMENTAL
Intervention: Albuterol (QID + PRN)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo (PRN)
Number of subjects: 17
Study: 1558794

Group type: EXPERIMENTAL
Intervention: Mitoxantrone (12 mg m‐2) administered via a 10 min i.v. infusion to 8 women (10 kinetics)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: High-dose mitoxantrone associated with high-dose alkylating agents administered to 7 women (7 kinetics)
Number of subjects: 15

Group type: COMPARATOR
Intervention: High-dose mitoxantrone
Number of subjects: 15
Study: 2862820

Group type: EXPERIMENTAL
Intervention: 2SHRZ (streptomycin, isoniazid, rifampin, and pyrazinamide for 2 months)
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: 1SHRZ (isoniazid, rifampin, and pyrazinamide for 1 month)
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: 2HRZ (isoniazid, rifampin, and pyrazinamide for 2 months without streptomycin)
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: H3R3 (3‐times‐weekly isoniazid and rifampin up to 6 months)
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Patients with drug‐sensitive tubercle bacilli
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Patients with tubercle bacilli resistant to isoniazid, streptomycin, or both
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 319
Study: 31353272

Group type: EXPERIMENTAL
Intervention: Preoperative counseling and information sources
Number of subjects: 99
Study: 30287676

Group type: COMPARATOR
Intervention: US$0 (control)
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: US$1.25
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: US$2.50
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: US$5.00
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: US$10.00
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: All arms (including control)
Number of subjects: 800
Study: 23440660

Group type: EXPERIMENTAL
Intervention: Cynara scolymus extract (600 mg/d)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 23364498

Group type: EXPERIMENTAL
Intervention: Light Intervention Group (LIG) - 90 nursing homes, 3,258 participants
Number of subjects: 6275

Group type: EXPERIMENTAL
Intervention: Strong Intervention Group (SIG) - 85 nursing homes, 3,017 participants
Number of subjects: 6275

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 6275
Study: 20495438

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18817803

Group type: EXPERIMENTAL
Intervention: Groups that slept between sessions
Number of subjects: 5

Group type: COMPARATOR
Intervention: Groups that did not sleep between sessions
Number of subjects: 5
Study: 15985573

Group type: EXPERIMENTAL
Intervention: Testosterone (100 mg T enanthate, weekly intramuscular injections)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo (saline, weekly injections)
Number of subjects: 32
Study: 12974980

Group type: EXPERIMENTAL
Intervention: Sufentanil infusion
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Sufentanil plus magnesium infusion
Number of subjects: 30
Study: 10389848

Group type: EXPERIMENTAL
Intervention: Trp64Arg variant group (n=23)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Normal allele group (n=19)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Trp64Arg variant in never-obese women (n=16)
Number of subjects: 42
Study: 8902989

Group type: EXPERIMENTAL
Intervention: Vidas D‐Di assay
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Instant IA D‐Di assay
Number of subjects: 171

Group type: COMPARATOR
Intervention: Latex agglutination technique
Number of subjects: 171

Group type: COMPARATOR
Intervention: Nycocard D‐Dimer assay
Number of subjects: 171

Group type: COMPARATOR
Intervention: Classic ELISA methods (Stago, Organon, Behring)
Number of subjects: 171
Study: 1894763

Group type: EXPERIMENTAL
Intervention: Continuous cimetidine (50 mg/hr IV)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intermittent cimetidine (300 mg IV over 15 minutes every 6 hours)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (aminophylline 0.9 mg/kg/hr over 6 hours)
Number of subjects: 12
Study: 6275987

Group type: EXPERIMENTAL
Intervention: CAVP16 (regimen I)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: CAVP16 followed by COMP (regimen II)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Cranial irradiation
Number of subjects: 109

Group type: COMPARATOR
Intervention: Observation only (for cranial irradiation group)
Number of subjects: 109
Study: 30993680

Group type: EXPERIMENTAL
Intervention: Buccally absorbed prochlorperazine (BAP) 6 mg plus 2.25 mL saline IV placebo
Number of subjects: 80

Group type: COMPARATOR
Intervention: Intravenous prochlorperazine (IVP) 10 mg and buccally absorbed saccharine pill placebo
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Buccally absorbed prochlorperazine (BAP)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Intravenous prochlorperazine (IVP)
Number of subjects: 80
Study: 29900913

Group type: EXPERIMENTAL
Intervention: Lycopene (4 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Curcumin (300 mg thrice daily)
Number of subjects: 60
Study: 27217703

Group type: EXPERIMENTAL
Intervention: Plasma long noncoding RNAs (lncRNAs)
Number of subjects: 0
Study: 25005901

Group type: EXPERIMENTAL
Intervention: Parent involvement during anamnesis and recommendations for home exercises
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Therapists' attitudes toward working with parents
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Reasons for limited parent involvement
Number of subjects: 53
Study: 21929834

Group type: EXPERIMENTAL
Intervention: Cinnamomum zeylanicum (6 g)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 19114869

Group type: EXPERIMENTAL
Intervention: CD4 cell-driven scheduled treatment interruption (STI)
Number of subjects: 329

Group type: COMPARATOR
Intervention: Continuous HAART (control)
Number of subjects: 329
Study: 17213964

Group type: EXPERIMENTAL
Intervention: Moderate intensity (MOD, n = 13, 5 sessions per week, 30 min each, intensity 90 % of the anaerobic threshold)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Low intensity (LOW, n = 13, 5 sessions per week, intensity 15 bpm below MOD)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control (CO, n = 13, no training)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Moderate intensity (MOD)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Low intensity (LOW)
Number of subjects: 39
Study: 15878306

Group type: EXPERIMENTAL
Intervention: ICES (International Classification of Epileptic Seizures)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: PDSS (Proposal of a New Diagnostic Scheme for Seizures)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: SSC (Semiological Seizure Classification)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Experience with epilepsy surgery
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Reliability analysis for ICES
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Reliability analysis for PDSS
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Reliability analysis for SSC
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Preference questionnaire results
Number of subjects: 28
Study: 12466187

Group type: EXPERIMENTAL
Intervention: Hormonal contraceptive methods (specifics not provided)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Condoms
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vasectomy
Number of subjects: 0
Study: 9607840

Group type: EXPERIMENTAL
Intervention: Azithromycin (1 g)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Ciprofloxacin (500 mg)
Number of subjects: 17
Study: 7694905

Group type: EXPERIMENTAL
Intervention: ECT three times weekly
Number of subjects: 52

Group type: COMPARATOR
Intervention: ECT twice weekly
Number of subjects: 52
Study: 2151277

Group type: EXPERIMENTAL
Intervention: Zoladex plus flutamide
Number of subjects: 304

Group type: COMPARATOR
Intervention: Zoladex
Number of subjects: 304
Study: 638627

Group type: EXPERIMENTAL
Intervention: Mobile Coronary Care Unit (MCCU)
Number of subjects: 3340

Group type: COMPARATOR
Intervention: Routine transport
Number of subjects: 3340

Group type: COMPARATOR
Intervention: Routine ambulances (general practitioners' patients)
Number of subjects: 3340
Study: 30242234

Group type: EXPERIMENTAL
Intervention: Muscle insulin sensitivity index (MISI)
Number of subjects: 640

Group type: EXPERIMENTAL
Intervention: Hepatic insulin resistance index (HIRI)
Number of subjects: 640

Group type: EXPERIMENTAL
Intervention: Odd-chain/even-chain TAG ratio
Number of subjects: 640

Group type: EXPERIMENTAL
Intervention: Very-long-chain/long-chain TAG ratio
Number of subjects: 640

Group type: EXPERIMENTAL
Intervention: TAG levels
Number of subjects: 640
Study: 28056540

Group type: EXPERIMENTAL
Intervention: Children's book about SHSe distributed to patients
Number of subjects: 7

Group type: COMPARATOR
Intervention: No materials provided (Control group)
Number of subjects: 7
Study: 25986137

Group type: EXPERIMENTAL
Intervention: Physician-patient intervention (n = 167)
Number of subjects: 503

Group type: COMPARATOR
Intervention: Physician-only intervention (n = 183)
Number of subjects: 503

Group type: COMPARATOR
Intervention: Usual care (n = 153)
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Physician-patient intervention
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: All arms
Number of subjects: 503
Study: 23239301

Group type: EXPERIMENTAL
Intervention: Salient haptic skills simulator (training on grasping, probing, and sweeping)
Number of subjects: 30
Study: 20796077

Group type: EXPERIMENTAL
Intervention: n‐6 polyunsaturated fatty acids (PUFA) diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saturated fatty acids (SFA) diet
Number of subjects: 0
Study: 19209987

Group type: EXPERIMENTAL
Intervention: Foster care
Number of subjects: 3

Group type: COMPARATOR
Intervention: Institutionalized children
Number of subjects: 3

Group type: COMPARATOR
Intervention: Family-reared children
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 3
Study: 18044198

Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Number of subjects: 213
Study: 15671129

Group type: EXPERIMENTAL
Intervention: Oral risperidone 2‐6 mg/day
Number of subjects: 75

Group type: COMPARATOR
Intervention: Oral zuclopenthixol 20‐50 mg/day
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Both groups (risperidone and zuclopenthixol)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Oral risperidone
Number of subjects: 75

Group type: COMPARATOR
Intervention: Oral zuclopenthixol
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 75
Study: 12021218

Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg once daily)
Number of subjects: 112000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112000
Study: 9535526

Group type: EXPERIMENTAL
Intervention: Robot-aided therapy
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Peripheral manipulation of the impaired limb
Number of subjects: 20
Study: 7656119

Group type: EXPERIMENTAL
Intervention: Sertraline 50 mg for every 20 mg of fluoxetine
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Sertraline 75 mg for every 20 mg of fluoxetine
Number of subjects: 45

Group type: COMPARATOR
Intervention: Fluoxetine (control group)
Number of subjects: 45
Study: 2502789

Group type: EXPERIMENTAL
Intervention: Ethanol (0.56 g/kg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 170521

Group type: EXPERIMENTAL
Intervention: Photodynamic inactivation with neutral red and light
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 31056357

Group type: EXPERIMENTAL
Intervention: Intervention group with intraoperative cerebral oximetry monitoring and intervention protocol for cerebral oxygen desaturation.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group with hidden cerebral oximetry data and no intervention protocol.
Number of subjects: 0
Study: 30279332

Group type: EXPERIMENTAL
Intervention: Mushroom diet
Number of subjects: 32

Group type: COMPARATOR
Intervention: Meat diet
Number of subjects: 32
Study: 29176684

Group type: EXPERIMENTAL
Intervention: Verum acupuncture
Number of subjects: 26

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 26
Study: 26139640

Group type: EXPERIMENTAL
Intervention: Celecoxib (200 mg twice daily)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Diclofenac (50 mg twice daily)
Number of subjects: 52
Study: 23945051

Group type: EXPERIMENTAL
Intervention: Full-mouth supra-gingival and sub-gingival non-surgical scaling and root planing, followed by systemic antibiotic therapy, local antiseptics, and oral hygiene instructions.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group will receive the same intervention after the 3-month follow-up period.
Number of subjects: 40
Study: 21937420

Group type: EXPERIMENTAL
Intervention: Somatostatin pretreatment
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 18312984

Group type: EXPERIMENTAL
Intervention: Heated humidified carbon dioxide
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard cold dry gas (control group)
Number of subjects: 60
Study: 16861054

Group type: EXPERIMENTAL
Intervention: Walking (40 min at moderate intensity, 5 times a week from 18 weeks gestation until birth)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stretching (40 min without increasing heart rate to more than 10% of resting heart rate, 5 times a week from 18 weeks gestation until birth)
Number of subjects: 0
Study: 12702550

Group type: EXPERIMENTAL
Intervention: Interleukin-2 (IL-2) 225,000 IU twice daily for 30 days
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Interleukin-2 (IL-2)
Number of subjects: 110
Study: 10787208

Group type: EXPERIMENTAL
Intervention: C-arm CT fluoroscopy
Number of subjects: 18

Group type: COMPARATOR
Intervention: Conventional fluoroscopy
Number of subjects: 18
Study: 8877242

Group type: EXPERIMENTAL
Intervention: Ranitidine at a dose of 9.3 +/- 0.9 mg/kg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ranitidine at a dose of 14.8 +/- 3.9 mg/kg/day
Number of subjects: 0
Study: 1686656

Group type: EXPERIMENTAL
Intervention: 30 mg remoxipride
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 60 mg remoxipride
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 120 mg remoxipride
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 6628584

Group type: EXPERIMENTAL
Intervention: Becotide inhalation
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Salbutamol pretreatment followed by Becotide inhalation
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Becotide
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo and Aldecine aerosols
Number of subjects: 17
Study: 31017637

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg orally twice daily
Number of subjects: 5022

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5022
Study: 30058377

Group type: EXPERIMENTAL
Intervention: Micronized dehydrated human amnion/chorion membrane (dHACM) injection
Number of subjects: 145

Group type: COMPARATOR
Intervention: 0.9% sodium chloride placebo
Number of subjects: 145
Study: 27783918

Group type: EXPERIMENTAL
Intervention: Long-term supplemental oxygen (24-hour oxygen for resting desaturation; oxygen during exercise and sleep for exercise-induced desaturation)
Number of subjects: 738

Group type: COMPARATOR
Intervention: No long-term supplemental oxygen
Number of subjects: 738

Group type: EXPERIMENTAL
Intervention: Long-term supplemental oxygen
Number of subjects: 738
Study: 25358095

Group type: EXPERIMENTAL
Intervention: e-cig groups
Number of subjects: 48

Group type: COMPARATOR
Intervention: control group
Number of subjects: 48
Study: 21933851

Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplantation (n = 61)
Number of subjects: 247

Group type: COMPARATOR
Intervention: Chemotherapy-only (intensification and maintenance therapy; n = 186)
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplantation for patients with 11q23 aberrations (n = 18)
Number of subjects: 247

Group type: COMPARATOR
Intervention: Chemotherapy-only for patients with 11q23 aberrations (n = 49)
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplantation for patients without 11q23 aberrations
Number of subjects: 247

Group type: COMPARATOR
Intervention: Chemotherapy-only for patients without 11q23 aberrations
Number of subjects: 247
Study: 19637250

Group type: EXPERIMENTAL
Intervention: Scalp cooling
Number of subjects: 266

Group type: COMPARATOR
Intervention: No scalp cooling (Control)
Number of subjects: 266
Study: 17607101

Group type: EXPERIMENTAL
Intervention: ACD with fusion using a semirigid plate
Number of subjects: 20

Group type: COMPARATOR
Intervention: Simple anterior microdiscectomy (ACD)
Number of subjects: 20
Study: 16105246

Group type: EXPERIMENTAL
Intervention: Meaningful irrelevant speech
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Road traffic noise
Number of subjects: 4

Group type: COMPARATOR
Intervention: Quiet
Number of subjects: 4
Study: 12398165

Group type: EXPERIMENTAL
Intervention: Calcium hydroxide points
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Calcium hydroxide paste
Number of subjects: 46

Group type: COMPARATOR
Intervention: Free-floating (planktonic) cultures
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Biofilm bacteria
Number of subjects: 46
Study: 9952363

Group type: EXPERIMENTAL
Intervention: dideoxyinosine (ddI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: zidovudine+ddI
Number of subjects: 0

Group type: COMPARATOR
Intervention: zidovudine monotherapy
Number of subjects: 0
Study: 7477798

Group type: EXPERIMENTAL
Intervention: Etomidate (0.30 mg/kg IV induction, 0.02 mg/kg/min continuous infusion for 24-72 hours)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Pentobarbital (not detailed in dosage or duration)
Number of subjects: 7
Study: 2154925

Group type: EXPERIMENTAL
Intervention: Live attenuated oral rhesus Rotavirus candidate vaccine (strain MMU 18006 [lot RRV‐1])
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 7294770

Group type: EXPERIMENTAL
Intervention: Gentamicin
Number of subjects: 201

Group type: COMPARATOR
Intervention: Tobramycin
Number of subjects: 201
Study: 30111253

Group type: EXPERIMENTAL
Intervention: D-cycloserine (DCS)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 28535707

Group type: EXPERIMENTAL
Intervention: Macular pigment optical density (MPOD)
Number of subjects: 56
Study: 27746305

Group type: EXPERIMENTAL
Intervention: Dusquetide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24793722

Group type: EXPERIMENTAL
Intervention: Antenatal magnesium sulfate
Number of subjects: 1771

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1771
Study: 22848006

Group type: EXPERIMENTAL
Intervention: Testosterone therapy (1000 mg testosterone undecanoate, n=33)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo (n=34)
Number of subjects: 67
Study: 20337081

Group type: EXPERIMENTAL
Intervention: Lingual split bone technique
Number of subjects: 150

Group type: COMPARATOR
Intervention: High speed turbine bodkin boneless technique
Number of subjects: 150
Study: 17373972

Group type: EXPERIMENTAL
Intervention: Calcitriol 3 microg/g ointment
Number of subjects: 250

Group type: COMPARATOR
Intervention: Calcipotriol 50 microg/g ointment
Number of subjects: 250
Study: 15957724

Group type: EXPERIMENTAL
Intervention: Combination of low dose oral midazolam (0.25 mg/kg) and low dose oral ketamine (3 mg/kg)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Oral midazolam (0.5 mg/kg)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Oral ketamine (6 mg/kg)
Number of subjects: 72
Study: 12024143

Group type: EXPERIMENTAL
Intervention: ERCP/PTC
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: MRCP
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: CT
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: EUS
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Combination of MRCP and EUS
Number of subjects: 50
Study: 9689426

Group type: EXPERIMENTAL
Intervention: Paracetamol/codeine fixed-dose combination (500 mg paracetamol and 30 mg codeine phosphate)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Tramadol (50 mg tramadol hydrochloride)
Number of subjects: 55
Study: 8580228

Group type: EXPERIMENTAL
Intervention: Phototherapy treatment for 1 week
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Phototherapy treatment for 2 weeks
Number of subjects: 26
Study: 2669436

Group type: EXPERIMENTAL
Intervention: Topical indomethacin
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 52
Study: 1265780

Group type: EXPERIMENTAL
Intervention: Infusion of 1g Podophyllum/day after irradiation (128 patients)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: 1g Acethyl-homocystein-thiolactone (AHCT) prior to irradiation and Podophyllum after exposure (46 patients)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 256
Study: 30768673

Group type: EXPERIMENTAL
Intervention: Inpatient multicomponent rehabilitation (3.5 weeks or 4+4 days)
Number of subjects: 334

Group type: COMPARATOR
Intervention: Outpatient cognitive behavioural therapy (6 sessions/6 weeks)
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: FABQ-work scores at baseline
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: FABQ-work scores (consistently low)
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: FABQ-work scores (reduced)
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: FABQ-work scores (increased or consistently high)
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: FABQ-physical activity subscale
Number of subjects: 334
Study: 27488830

Group type: EXPERIMENTAL
Intervention: CCM Express Indirect Calorimeter
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: QUARK RMR ICU Indirect Calorimeter
Number of subjects: 30